|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Eagle’s Eye View: Underdiagnosis of AFib in Black Adults; Echocardiographic Evaluation; CAC Scores in Young Adults; Add-On Treatments For Resistant HypertensionIn this week’s View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib).
- Safety and Efficacy of ProtEmbo Device; TAVR vs. SAVR in Patients with Symptomatic Severe AR at 1 YearThe ProtEmbo Cerebral Protection System met its primary safety endpoint but failed to meet its primary efficacy endpoint, adding to uncertainty regarding the routine use of cerebral embolic protection (CEP) in TAVR, according to findings from the PROTEMBO IDE trial presented on the final day of TCT 2026.
- EPIC17-VERONICA: Can Platelet Function Testing Guide P2Y12i Deescalation?In patients deemed to have very low platelet reactivity, switching from more potent P2Y12 inhibitors to clopidogrel did not improve outcomes at one year, according to findings from the EPIC17-VERONICA trial presented at TCT 2026.
- DUOTAP: Routine Postdilation May Optimize THV Geometry, HemodynamicsRoutine postdilation with a balloon-expandable transcatheter heart valve (THV) optimized THV geometry and improved hemodynamic performance, without increasing procedure-related adverse events in patients with severe aortic stenosis (AS), according to results from the DUOTAP trial presented at TCT 2026 and simultaneously published in JAMA Cardiology.
- ENCIRCLE: Two-Year Results Following Transeptal TMVR in Patients With Severe MRPatients with symptomatic mitral regurgitation (MR) who underwent full percutaneous transseptal transcatheter mitral valve replacement (TMVR) with the SAPIEN M3 system continued to see durable near MR elimination and sustained improvements in functional and health status outcomes at two years...



